Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1006Uterine Cervical Neoplasms 420Endometrial Neoplasms 350Carcinoma, Non-Small-Cell Lung 292Breast Neoplasms 292Neoplasms 238Colorectal Neoplasms 233Fallopian Tube Neoplasms 211Stomach Neoplasms 192Pancreatic Neoplasms 184Melanoma 157Prostatic Neoplasms 152Triple Negative Breast Neoplasms 148Carcinoma, Ovarian Epithelial 147Lung Neoplasms 136Neoplasm Metastasis 133Squamous Cell Carcinoma of Head and Neck 131Carcinoma, Renal Cell 130Head and Neck Neoplasms 122Esophageal Neoplasms 121Urinary Bladder Neoplasms 112Small Cell Lung Carcinoma 90Sarcoma 80Carcinoma, Hepatocellular 76Recurrence 70Carcinoma, Transitional Cell 70Uterine Cervical Dysplasia 66Papillomavirus Infections 66Colonic Neoplasms 59Cholangiocarcinoma 59

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Metastatic Breast Cancer × Gynecologic × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡